sorafenib has been researched along with sulfinpyrazone in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (sulfinpyrazone) | Trials (sulfinpyrazone) | Recent Studies (post-2010) (sulfinpyrazone) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,122 | 172 | 32 |
| Protein | Taxonomy | sorafenib (IC50) | sulfinpyrazone (IC50) |
|---|---|---|---|
| fMet-Leu-Phe receptor | Homo sapiens (human) | 14.4 | |
| fMet-Leu-Phe receptor | Homo sapiens (human) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
1 other study(ies) available for sorafenib and sulfinpyrazone
| Article | Year |
|---|---|
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |